Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Supporters

This activity is supported by educational grants from Celgene Corporation and Lilly USA, LLC.

7th Annual New York Lung Cancer Symposium®

7th Annual New York Lung Cancer Symposium®


The 7th Annual New York Lung Cancer Symposium® is a one-day meeting which will serve as an update on advances in the field and will focus on the future of lung cancer treatment including: molecular subsets, targeted agents in development, treatment options in early stage, screening, the ongoing guideline debate, and a look forward from the experts.

Participants will learn from engaging presentations delivered by thought leaders and by reviewing and discussing realistic and complex scenarios, sharing clinical experiences, understanding well-established and emerging unmet therapeutic opportunities, solving clinical problems, and clarifying best practices. Participants will actively respond to and interact with the faculty through informal questions and open discussion, and as a result of this approach will leave with a higher level of understanding than they would otherwise achieve.

Target Audience

This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists involved in the treatment and management of patients with lung cancer.  Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer may also participate.

Learning Objectives

  • Evaluate emerging clinical data regarding new agents and evolving strategies for the treatment of lung cancer, and apply clinical trial data appropriately in order to optimize the outcome of individual patients
  • Use histologic and molecular data, tumor and patient characteristics, in order to individualize therapy choices for your patients with NSCLC


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

In case of onsite emergency:

Professional Information


Calendar of Events
Filter By